It was several months ago when entrepreneur, hedge fund operator, and financial and pharmaceutical executive Martin Shkreli made the news for amping up the prices for Daraprim, an antiparasitic drug, from $13.50 to $750.00, after purchasing the manufacturing license. After being called about for the dastardly and heartless deed by the media, he seemed to thrive... Continue Reading →